Slide 1: Targeted science, Tailored solutions
Targeted science, Tailored solutions for people with autoimmune disease IMVT-1402 Initial First-in-human Data Presentation September 26, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “ex
Slide 3: Our Vision: Normal Lives for People with Autoimmune Disease
Our Vision: Normal Lives for People with Autoimmune Disease What we do: We are developing targeted therapies that are designed to address the complex and variable needs of people with autoimmune diseases. Love Bolder, All Trailblazing Faster Voices 3
Slide 4: IMVT-1402 Was Selected to Deliver Maximum IgG Reduction While Minimizing Interference with Albumin Recycling
IMVT-1402 Was Selected to Deliver Maximum IgG Reduction While Minimizing Interference with Albumin Recycling IMVT-1402: overlay with albumin and Fc Batoclimab: overlay with albumin and Fc FcRn FcRn Albumin Fc Albumin Fc IMVT-1402 Batoclimab Note: Ribbon representations generated from X-Ray crystal s
Slide 5: Goals for the Phase 1 Program
Goals for the Phase 1 Program Demonstrate potential best-in-class IgG reductions similar to batoclimab Demonstrate minimal to no impact on albumin Demonstrate minimal to no impact on LDL Achieve all of the above with a simple, commercially attractive subcutaneous injection Note: Based on data to dat
Slide 6: Best-in-Class Potential for IMVT-1402 as FcRn Inhibitor Highlighted by Initial Phase 1 Safety and Pharmacodynamic Data
Best-in-Class Potential for IMVT-1402 as FcRn Inhibitor Highlighted by Initial Phase 1 Safety and Pharmacodynamic Data Initial SAD and 300 mg MAD data demonstrated deep and rapid IgG reduction, similar to batoclimab, with 63% mean IgG reduction in the 300 mg MAD cohort after four doses Initial 300 m
Slide 7: IMVT-1402 Phase 1 Clinical Trial Objectives
IMVT-1402 Phase 1 Clinical Trial Objectives 1 2 3 Expeditiously Validate the Confirm doses evaluate safety, IMVT-1402 dose for future studies pharmacokinetic & that achieves pharmacodynamic FcRn saturation profile 7
Slide 8: Study Design for IMVT-1402 Phase 1 Clinical Trial in Healthy Volunteers
Study Design for IMVT-1402 Phase 1 Clinical Trial in Healthy Volunteers* Single-Ascending Single-Ascending Multiple-Ascending Intravenous Dose Subcutaneous Dose Subcutaneous Dose Fixed 1,200 mg Fixed 600 mg Fixed 600 mg Fixed 600 mg Fixed 300 mg Fixed 300 mg Fixed 300 mg Fixed 100 mg Single Ascendin
Slide 9: Single-Ascending Subcutaneous Doses
Single-Ascending Subcutaneous Doses 9
Slide 10: IMVT-1402 SAD Data Suggests Potential Best-in-Class IgG Reduction Similar to Batoclimab
IMVT-1402 SAD Data Suggests Potential Best-in-Class IgG Reduction Similar to Batoclimab IgG % change from baseline* IMVT-1402: Single-ascending SC Dose Batoclimab: Single-ascending SC Dose 40% 40% 20% 20% 0% 0% -20% -20% -40% -40% -60% -60% -80% -80% -100% -100% 0 10 20 30 0 10 20 30 Day Day IMVT-14
Slide 11: IMVT-1402 SAD Data Suggests Potential Best-in-Class IgG Reduction Similar to Batoclimab
IMVT-1402 SAD Data Suggests Potential Best-in-Class IgG Reduction Similar to Batoclimab IgG % change from baseline* Single-ascending SC Dose 40% 20% 0% -20% -40% -60% -80% -100% 0 10 20 30 Day IMVT-1402: 600mg Group Mean IMVT-1402: 300mg Group Mean IMVT-1402: Placebo (Pooled) Group Mean Batoclimab:
Slide 12: IMVT-1402 Produced a Similar Effect on Albumin as Placebo
IMVT-1402 Produced a Similar Effect on Albumin as Placebo Albumin % change from baseline* IMVT-1402: Single-ascending SC Dose Batoclimab: Single-ascending SC Dose 25% 25% 20% 20% 15% 15% 10% 10% 5% 5% 0% 0% -5% -5% -10% -10% -15% -15% -20% -20% -25% -25% 0 10 20 30 0 10 20 30 Day Day IMVT-1402: 600m
Slide 13: IMVT-1402 Produced a Similar Effect on LDL as Placebo
IMVT-1402 Produced a Similar Effect on LDL as Placebo LDL % change from baseline* IMVT-1402: Single-ascending SC Dose 50% 40% 30% 20% 10% 0% -10% -20% -30% -40% -50% 0 10 20 30 Day IMVT-1402: 600mg Group Mean IMVT-1402: 300mg Group Mean IMVT-1402: Placebo (Pooled) Group Mean No LDL values in the IMV
Slide 14: Multiple-Ascending Subcutaneous Doses
Multiple-Ascending Subcutaneous Doses (Once-weekly dosing x 4 weeks) 14
Slide 15: IMVT-1402 300 mg MAD Data Suggests Potential Best-in-Class IgG Reduction Similar to Batoclimab
IMVT-1402 300 mg MAD Data Suggests Potential Best- in-Class IgG Reduction Similar to Batoclimab IgG % change from baseline* IMVT-1402: Multiple-ascending SC Dose Batoclimab: Multiple-ascending SC Dose 40% 40% 20% 20% 0% 0% -20% -20% -40% -40% -60% -60% -80% -80% -100% -100% 0 10 20 30 0 10 20 30 Day
Slide 16: IMVT-1402 300 mg MAD Data Suggests Potential Best-in-Class IgG Reduction Similar to Batoclimab
IMVT-1402 300 mg MAD Data Suggests Potential Best- in-Class IgG Reduction Similar to Batoclimab IgG % change from baseline* Multiple-ascending SC Dose 40% 20% 0% -20% -40% -60% -80% -100% 0 10 20 30 Day 600 placeholder IMVT-1402: 300mg Group Mean IMVT-1402: Placebo Group Mean Batoclimab: 680mg Group
Slide 17: IMVT-1402 300 mg MAD Data: No Albumin Reduction Compared to Baseline After Four Weeks
IMVT-1402 300 mg MAD Data: No Albumin Reduction Compared to Baseline After Four Weeks of Dosing Albumin % change from baseline* IMVT-1402: Multiple-ascending SC Dose Batoclimab: Multiple-ascending SC Dose 20% 20% 10% 10% 0% 0% -10% -10% -20% -20% -30% -30% -40% -40% 0 10 20 30 0 10 20 30 Day Day Bat
Slide 18: IMVT-1402 300 mg MAD Data: No LDL Increase Compared to Baseline After Four Weeks
IMVT-1402 300 mg MAD Data: No LDL Increase Compared to Baseline After Four Weeks of Dosing LDL % change from baseline* IMVT-1402: Multiple-ascending SC Dose 50% 40% 30% 20% 10% 0% -10% -20% -30% -40% -50% 0 10 20 30 Day IMVT-1402: 300mg Group Mean IMVT-1402: Placebo Group Mean No LDL values in the I
Slide 19: IMVT-1402 Showed a Favorable Safety Profile in SAD / MAD Initial Data Set
IMVT-1402 Showed a Favorable Safety Profile in SAD / MAD Initial Data Set IV SAD SC SAD SC MAD Placebo 100mg 300mg 600mg Placebo 300mg 600mg Placebo 300mg N=6 N=6 N=6 N=6 N=4 N=6 N=6 N=2 N = 10 n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) Participants with at least one TEAE 4 (67) 4 (67) 3
Slide 20: Concluding Thoughts
; Concluding Thoughts Ea nike
Slide 21: Summary of IMVT-1402 SAD/MAD Data Reviewed
Summary of IMVT-1402 SAD/MAD Data Reviewed IMVT-1402 SAD/MAD data to IMVT-1402 SAD/MAD data to date suggest potential for date suggest potential best- best-in-class IgG lowering case profile with respect to with IMVT-1402 albumin and LDL impact IMVT-1402 data appeared similarly No reduction in album
Slide 22: IMVT-1402 Has Potentially Best-In-Class Attributes to Address Large Unmet Need in Autoimmune Disease
IMVT-1402 Has Potentially Best-In-Class Attributes to Address Large Unmet Need in Autoimmune Disease IMVT-1402 + + Deep IgG Lowering Initial Phase 1 data suggests deep + dose-dependent IgG lowering similar to batoclimab Favorable Analyte Profile Initial Phase 1 data supports a favorable analyte prof
Slide 23: Concluding Thoughts
Concluding Thoughts Anti-FcRn market Based on SAD / MAD 600mg SC offers many MAD data to date, cohort just starting attractive IMVT-1402 has a with data expected opportunities and potential best-in- in November 2023 a favorable class profile development path 23